GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (STU:VE11) » Definitions » Additional Paid-In Capital

Aravive (STU:VE11) Additional Paid-In Capital : €588.95 Mil(As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Aravive Additional Paid-In Capital?


Aravive's quarterly additional paid-in capital declined from Mar. 2023 (€586.05 Mil) to Jun. 2023 (€579.88 Mil) but then increased from Jun. 2023 (€579.88 Mil) to Sep. 2023 (€588.95 Mil).

Aravive's annual additional paid-in capital increased from Dec. 2020 (€451.04 Mil) to Dec. 2021 (€515.09 Mil) and increased from Dec. 2021 (€515.09 Mil) to Dec. 2022 (€591.68 Mil).


Aravive Additional Paid-In Capital Historical Data

The historical data trend for Aravive's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aravive Additional Paid-In Capital Chart

Aravive Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 448.74 485.24 451.04 515.09 591.68

Aravive Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 608.06 591.68 586.05 579.88 588.95

Aravive Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Aravive Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Aravive's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (STU:VE11) Business Description

Industry
Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.

Aravive (STU:VE11) Headlines

No Headlines